Greg Harrison
Stock Analyst at B of A Securities
(2.31)
# 2,556
Out of 4,859 analysts
87
Total ratings
47.69%
Success rate
-3.07%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Neutral | $321 → $315 | $285.22 | +10.44% | 3 | Jun 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Sector Outperform | $65 → $55 | $22.26 | +147.08% | 2 | Jun 2, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $32 → $9 | $3.17 | +184.36% | 7 | May 28, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $36 → $37 | $14.70 | +151.70% | 6 | May 28, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Sector Outperform | $32 | $12.80 | +150.00% | 1 | May 28, 2025 | |
| KROS Keros Therapeutics | Maintains: Sector Outperform | $41 → $26 | $13.71 | +89.64% | 5 | May 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $28 → $20 | $19.24 | +3.95% | 4 | May 8, 2025 | |
| GERN Geron | Downgrades: Sector Perform | $4 → $1.5 | $1.56 | -3.54% | 3 | May 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $450 → $442 | $459.47 | -3.80% | 6 | May 6, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $74 → $71 | $34.95 | +103.18% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $52 → $55 | $39.56 | +39.03% | 6 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $338 → $342 | $306.99 | +11.40% | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $17.63 | +126.89% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $52.62 | +42.53% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $27 → $32 | $14.66 | +118.28% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $8.98 | +100.45% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $8.95 | +145.81% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $8.41 | +982.69% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.69 | +2.65% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.50 | +201.81% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $15.28 | +155.24% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.26 | +563.72% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $3.56 | -15.73% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $2.98 | +2,248.99% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $29.60 | -72.97% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $18.01 | +199.83% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $8.93 | -32.81% | 5 | Mar 14, 2022 |
United Therapeutics
Jun 11, 2025
Maintains: Neutral
Price Target: $321 → $315
Current: $285.22
Upside: +10.44%
Vera Therapeutics
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $22.26
Upside: +147.08%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Buy
Price Target: $32 → $9
Current: $3.17
Upside: +184.36%
Liquidia
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $14.70
Upside: +151.70%
Arcturus Therapeutics Holdings
May 28, 2025
Initiates: Sector Outperform
Price Target: $32
Current: $12.80
Upside: +150.00%
Keros Therapeutics
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $13.71
Upside: +89.64%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $19.24
Upside: +3.95%
Geron
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.56
Upside: -3.54%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $450 → $442
Current: $459.47
Upside: -3.80%
Agios Pharmaceuticals
May 2, 2025
Maintains: Sector Outperform
Price Target: $74 → $71
Current: $34.95
Upside: +103.18%
Apr 30, 2025
Maintains: Sector Outperform
Price Target: $52 → $55
Current: $39.56
Upside: +39.03%
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $306.99
Upside: +11.40%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $17.63
Upside: +126.89%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $52.62
Upside: +42.53%
Feb 12, 2025
Maintains: Sector Outperform
Price Target: $27 → $32
Current: $14.66
Upside: +118.28%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $8.98
Upside: +100.45%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $8.95
Upside: +145.81%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $8.41
Upside: +982.69%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.69
Upside: +2.65%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.50
Upside: +201.81%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $15.28
Upside: +155.24%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.26
Upside: +563.72%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $3.56
Upside: -15.73%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $2.98
Upside: +2,248.99%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $29.60
Upside: -72.97%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $18.01
Upside: +199.83%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $8.93
Upside: -32.81%